The above results all suggest that an inflammatory immune environment forms in the tumors of IL-1-MT COAD patients, which may be a potential mechanism for these patients to have favorable clinical benefits after receiving ICIs. This evidence concerns the gene IL1A and colon adenocarcinoma.